Brief: Neximmune To Explore The Use Of Aim™ Direct Injection Technology In Type 1 Diabetes
09/08/2021 21:09
Aug 9 (Reuters) - Neximmune Inc NEXI.O :
* NEXIMMUNE TO EXPLORE THE USE OF AIM™ DIRECT INJECTION
TECHNOLOGY
IN TYPE 1 DIABETES
Source text for Eikon: ID:nGNX8dySrM
Further company coverage: NEXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neximmune
See all newsBrief: Neximmune Appointed Albert Marchio As Interim CFO
Brief: NexImmune and Agents Agreed To Terminate Sales Agreement & ATM Program dated June 2022
Brief: NexImmune Says Co Expects Existing Cash And Cash Equivalents Will Be Sufficient To Meet Its Anticipated Cash Requirements Through Mid-February 2024
Brief: Neximmune Gets Notice From Listing Qualifications Department Of Nasdaq
Brief: NexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual Meeting